© Denise Leong

The 17th International p53 Workshop

   8-12 July 2017
   Biopolis, Singapore

Home Registration & Poster Submission Program

Sponsors Venue Accommodation Travel Information See & Do in Singapore


The 17th International p53 Workshop
 

We cordially invite you to attend the 17th International p53 Workshop which will be held from 8 to 12 July 2017, at the Breakthrough Theatrette, Biopolis, Singapore. The conference will be hosted for the 1st time in Singapore in its 30 year history, and will have around 350-400 participants from around the world.

p53, the "Guardian of the Genome", is one of the most critical tumour suppressor genes preventing cancer formation, and hence, is the most mutated gene across all cancers. Cells with mutant p53 are more prone to be resistant to a variety of therapeutic targeting agents due to their ability to escape p53-mediated inhibitory effects on cellular growth.

The workshop will cover the latest developments in not only p53, but also its family members p63/p73. It aims to bring together scientists in these fields around the world to present and discuss novel basic, translational and clinical research. We hope that the advanced understanding of p53 will contribute to improved diagnosis and therapy of many types of cancers.

This workshop provides a great opportunity for the delegates to showcase their research, exchange new ideas; and get to meet fellow researchers and global partners for future collaborations. Your research will be seen by leaders from top pharmaceutical, biotech, academic and government institutes.

Kindly disseminate this information to your institutions and please do come and join us in this exciting workshop!


David Lane and Kanaga Sabapathy
On behalf of the Local Scientific Committee
 

Date :
8 to 12 July, 2017


Local Scientific Committee:

David LANE
Agency for Science, Technology and Research, Singapore

Kanaga SABAPATHY
National Cancer Centre, Singapore

Chandra VERMA
Bioinformatics Institute, A*STAR, Singapore

Koji ITAHANA
Duke-NUS Medical School, Singapore

Daniela RHODES
Nanyang Technological University, Singapore

Ito YOSHIAKI
Cancer Science Institute of Singapore, Singapore

Chit Fang CHEOK
IFOM - p53 Joint Research Lab, Singapore

International Scientific Committee:

Arnold LEVINE
Institute for Advanced Study, USA

Daniel ABERDAM
Université Paris Diderot, France

Laura ATTARDI
Stanford University, USA

Giovanni BLANDINO
Italian National Cancer Institute Regina Elena, Italy

Xinbin CHEN
UC Davis School of Veterinary Medicine, USA

Giannino DEL SAL
University of Trieste, Italy

Volker DOETSCH
Goethe University Frankfurt, Germany

Leif W. ELLISEN
Harvard Medical School, USA

Gerard EVAN
University of Cambridge, UK

Alan FERSHT
University of Cambridge, UK

Wei GU
Institute for Cancer Genetics, USA

Pierre HAINAUT
University of Grenoble, France

Curtis HARRIS
National Institutes of Health, USA

Ygal HAUPT
Peter MacCallum Cancer Centre, Australia

David KAPLAN
The Hospital for Sick Children, Canada

Sonia LAIN
Karolinska Institutet, Sweden

Scott LOWE
Memorial Sloan Kettering Cancer Center, USA

Guillermina LOZANO
The University of Texas MD Anderson Cancer Center, USA

Xin LU
Ludwig Institute for Cancer Research, UK

David MALKIN
The Hospital for Sick Children, Canada

Frank MCKEON
University of Houston, USA

Gerry MELINO
Medical Research Council, Toxicology Unit, Leicester, UK

Ute MOLL
Stony Brook University, USA

Moshe OREN
Weizmann Institute of Science, Israel

Jennifer A. PIETENPOL
Vanderbilt University Medical Center, USA

Carol PRIVES
Columbia University, USA

Michael RESNICK
National Institute of Environmental Health Sciences, USA

Varda ROTTER
Weizmann Institute of Science, Israel

Andreas STRASSER
Walter and Eliza Hall Institute of Medical Research, Australia

Karen VOUSDEN
Beatson Institute, UK

Klas WIMAN
Karolinska Institutet, Sweden

Gerard ZAMBETTI
St. Jude Children's Research Hospital, USA